Candriam S.C.A. Decreases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Candriam S.C.A. lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 78.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 50,610 shares of the medical device company’s stock after selling 179,841 shares during the quarter. Candriam S.C.A.’s holdings in DexCom were worth $3,936,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in DexCom by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after acquiring an additional 214,136 shares during the period. Jennison Associates LLC boosted its holdings in DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after acquiring an additional 710,858 shares during the period. Groupama Asset Managment boosted its holdings in DexCom by 1.1% in the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after acquiring an additional 31,358 shares during the period. Westfield Capital Management Co. LP boosted its holdings in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in DexCom by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock worth $219,716,000 after acquiring an additional 91,051 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and increased their target price for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Citigroup increased their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Wells Fargo & Company increased their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Stock Performance

Shares of DXCM opened at $77.84 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The business’s fifty day moving average price is $84.83 and its 200 day moving average price is $76.99. The stock has a market capitalization of $30.42 billion, a PE ratio of 54.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock valued at $3,309,794 over the last three months. Company insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.